Advertisement

Psychosis, Antipsychotic Medication, and Sexual Dysfunctions

  • Marc De Hert
  • Johan Detraux
Chapter
Part of the Trends in Andrology and Sexual Medicine book series (TASM)

Abstract

Sexual dysfunctions (SDs) in patients with psychoses are estimated to affect 30–80% of women and 45–80% of men, having a severe impact on their quality of life and medication adherence. Aim of this chapter was to critically review the findings on SDs induced by antipsychotics and by the symptoms of psychosis. Potential confounding factors, as genetic factors, comorbid psychiatric disorders, and the use of co-medications, were also accounted. Moreover, therapeutic approaches for the management of SDs in patients with psychosis were discussed.

References

  1. 1.
    Ostman M. Low satisfaction with sex life among people with severe mental illness living in a community. Psychiatry Res. 2014;216:340–5.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Chiesa A, Leucci V, Serretti A, et al. Antipsychotics and sexual dysfunction: epidemiology, mechanisms and management. Clin Neuropsychia. 2013;10(1):31–6.Google Scholar
  3. 3.
    Kalkavoura CS, Michopoulos I, Arvanitakis P, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21(4):332–41.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Just MJ. The influence of atypical antipsychotic drugs on sexual function. Neuropsychiatr Dis Treat. 2015;11:1655–61.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. A systematic review of instruments to measure sexual functioning in patients using antipsychotics. J Sex Res. 2014;51(4):383–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    De Hert M, Detraux J, Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf. 2014;13(5):605–24.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281–301.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des Devel Ther. 2012;6:107–15.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012;26(5 Suppl):42–51.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41(3):674–86.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29(4):353–62.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther. 2011;89(1):142–7.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009;19(8):542–50.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Kropp S, Ziegenbein M, Grohmann R, et al. Galactorrhea due to psychotropic drugs. Pharmacopsychiatry. 2004;37(Suppl 1):S84–8.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Mortimer A, Martin S, Lôo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19(2):63–9.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Malik P, Kemmler G, Hummer M, et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274–80.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130–40.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Montejo AL, Riesgo Y, Luque J, et al. Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr. 2010;38(1):13–21.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Hanssens L, L’Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;8:95.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Ziadi Trives M, Bonete Llácer JM, García Escudero MA, Martínez Pastor CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 2013;33(4):538–41.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244–53.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health. 2012;30(3):153–9.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;6:CD008296.Google Scholar
  25. 25.
    Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol. 2010;25(6):334–41.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    van Bruggen M, van Amelsvoort T, Wouters L, et al. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology. 2009;34(7):989–95.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Res. 2008;159(1–2):115–20.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31(3):340–6.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Bobes J, Garc A-Portilla MP, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125–47.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24(1):56–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Byerly MJ, Nakonezny PA, Bettcher BM, et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res. 2006;86(1–3):244–50.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Konarzewska B, Wołczyński S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009;34(1):129–39.PubMedCrossRefGoogle Scholar
  33. 33.
    Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Grande I, Hidalgo-Mazzei D, Nieto E, Mur M, Sàez C, Forcada I, Vieta E. Asenapine prescribing patterns in the treatment of manic in- and outpatients: results from the MANACOR study. Eur Psychiatry. 2015;30(4):528–34.PubMedCrossRefGoogle Scholar
  35. 35.
    SAPHRIS® (asenapine). Highlights of prescribing information. Silver Spring: U.S. Food and Drug Administration; 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022117s017s018s019lbl.pdf. Last Accessed 17 Sept 2015.
  36. 36.
    FANAPT® (iloperidone). Highlights of prescribing information. Silver Spring: U.S. Food and Drug Administration; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022192s013lbl.pdf. Last Accessed 17 Sept 2015.
  37. 37.
    Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):19–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm. 2011;68(4):301–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43–54.PubMedCrossRefGoogle Scholar
  40. 40.
    LATUDA® (lurasidone). Highlights of prescribing information. Silver Spring: U.S. Food and Drug Administration; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf. Last Accessed 17 Sept–Nov 2013.
  41. 41.
    Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology. 2013;225(3):519–30.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Shah SK. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ Med J (KUMJ). 2013;11:121–5.Google Scholar
  43. 43.
    Chaves KM, Serrano-Blanco A, Ribeiro SB, et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatr Q. 2013;84:125–35.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Yasui-Furukori N, Fujii A, Sugawara N, et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol. 2012;27:82–9.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Nebhinani N, Grover S, Avasthi A. Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire. Prim Care Companion CNS Disord. 2012;14:PCC.11m01199.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Kikuchi T, Iwamoto K, Sasada K, et al. Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;37:26–32.CrossRefGoogle Scholar
  47. 47.
    de Boer MK, Wiersma D, Bous J, et al. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J Clin Psychopharmacol. 2011;31:523–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Fujii A, Yasui-Furukori N, Sugawara N, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34:288–93.CrossRefGoogle Scholar
  49. 49.
    Montejo AL, Majadas S, Rico-Villademoros F, et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med. 2010;7:3404–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J Psychiatry. 2009;51:265–71.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28(6):418–23.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol. 2015;130:469–89.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Kelly DL, Wehring HJ, Earl AK, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated prolactin). BMC Psychiatry. 2013;13:214.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry. 1998;13(1 Suppl 1):23s–30s.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    De Hert M, Detraux J, Stubbs B. Antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures: a critical literature review. Expert Opin Drug Saf. 2015;15(6):809–23.CrossRefGoogle Scholar
  56. 56.
    De Hert M, Peuskens J, Sabbe T, Mitchell AJ, Stubbs B, Neven P, Wildiers H, Detraux J. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand. 2015;133(1):5–22.  https://doi.org/10.1111/acps.12459.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33(6):711–7.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170–9.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761–7.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):711–5.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Dickson RA, Dalby JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry. 1995;152(7):1102–3.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Liu-Seifert H, Kinon BJ, Tennant CJ, et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat. 2009;5:47–54.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(Suppl 2):55–68.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007;33(3):203–16.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Ali S, Miller KK, Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics. 2010;51(5):370–6.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008;5(12):2816–26.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57–61.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111–7.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Berry S, Martinez A, Myers J, et al. Serum prolactin in schizophrenia. Poster presented at the 7th world congress of biological psychiatry, July 1–6, 2001, Berlin, Germany.Google Scholar
  70. 70.
    Eberhard J, Lindström E, Holstad M, et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115(4):268–76.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Howes OD, Wheeler MJ, Pilowsky LS, et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2007;68(3):361–7.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Impot Res. 2005;17(2):201–3.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Lundberg PO, Hulter B. Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol. 1991;98(2):81–8.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002;111(1):11–20.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Smith SM. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol. 2008;22(2 Suppl):63–9.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008;22(2 Suppl):98–103.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22(2 Suppl):90–7.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Peluso MJ, Lewis SW, Barnes TR, et al. Non-neurological and metabolic side effects in the cost utility of the latest antipsychotics in schizophrenia randomised controlled trial (CUtLASS-1). Schizophr Res. 2013;144(1–3):80–6.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Reis Marques T, Smith S, Bonaccorso S, et al. Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry. 2012;201:131–6.CrossRefGoogle Scholar
  80. 80.
    Zemishlany Z, Weizman A. The impact of mental illness on sexual dysfunction. Adv Psychosom Med. 2008;29:89–106.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Zhang XR, Zhang ZJ, Zhu RX, et al. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011;12(8):1127–36.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Bosanac P, Castle DJ. Schizophrenia and depression. Med J Aust. 2013;199(6 Suppl):S36–9.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Pereira VM, Arias-Carrión O, Machado S, Nardi AE, Silva AC. Bupropion in the depression-related sexual dysfunction: a systematic review. CNS Neurol Disord Drug Targets. 2014;13:1079–88.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    La Torre A, Giupponi G, Duffy D, Conca A. Sexual dysfunction related to psychotropic drugs: a critical review – part I: antidepressants. Pharmacopsychiatry. 2013;46:191–9.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014;126:91–9.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29:259–66.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014;37:19–31.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Schmidt HM, Hagen M, Kriston L, et al. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev. 2012;11:CD003546.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639–61.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Knegtering R, Castelein S, Bruggeman R. Vaak seksuele functiestoornissen door antipsychotica, vooral bij prolactineverhoging. Resultaten van een aantal vergelijkende onderzoeken. Tijdschrift Voor Seksuologie. 2004;28:140–6.Google Scholar
  91. 91.
    Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050–7.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169(6):575–81.PubMedPubMedCentralGoogle Scholar
  93. 93.
    De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138–51.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Walters J, Jones I. Clinical questions and uncertainty – prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol. 2008;22(2 Suppl):82–9.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55(1):29–36.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Costa AM, Lima MS, Mari JD. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. 2006;124(5):291–7.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(Suppl 2):S108–14.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Howes O, Smith S. Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ. 2002;324(7348):1278.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008;69(Suppl 1):32–44.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Goffin V, Touraine P, Culler MD, et al. Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab. 2006;2(10):571–81.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(3):264–370.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    CYCLOSET® (bromocriptine mesylate). Highlights of prescribing information. Revised 7/2015. https://shared.salix.com/shared/pi/cycloset-pi.pdf?id=811731. Last Accessed 20 Oct 2015.
  103. 103.
    Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65(2):187–90.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Baeza Pertegaz I, Goikolea Alberdi JM, Parellada Rodón E. Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? J Psychiatry Neurosci. 2002;27(1):54.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry. 2008;30(4):378–80.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: meta-analysis of observational studies. Herz. 2013;38(8):868–80.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008;31(12):1119–23.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009;24(1):129–33.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Takashi T, Uchida H, Suzuki T, Mimura M. Effectiveness of saikokaryukotsuboreito (herbal medicine) for antipsychotic-induced sexual dysfunction in male patients with schizophrenia: a description of two cases. Case Rep Psychiatry. 2014;2014:784671.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Wang D, Wong HK, Zhang L, et al. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39(2):332–8.CrossRefGoogle Scholar
  111. 111.
    Yamada K, Kanba S, Yagi G, Asai M. Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. J Clin Psychopharmacol. 1997;17(3):234–5.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Mitsonis CI, Mitropoulos PA, Dimopoulos NP, et al. Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study. J Clin Psychiatry. 2008;69(2):206–12.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7(2):91–5.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Valevski A, Modai I, Zbarski E, Zemishlany Z, Weizman A. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin Neuropharmacol. 1998;21(6):355–7.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Aizenberg D, Shiloh R, Zemishlany Z, Weizman A. Low-dose imipramine for thioridazine-induced male orgasmic disorder. J Sex Marital Ther. 1996;22(3):225–9.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53.PubMedPubMedCentralGoogle Scholar
  117. 117.
    van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: a systematic review. J Psychopharmacol. 2015;29(8):857–66.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Universitair Psychiatrisch Centrum – Z.org KU Leuven, Department of Neurosciences, Campus KortenbergKortenbergBelgium

Personalised recommendations